Acute Kidney Injury Market, DelveInsight
Acute Kidney Injury therapies such as RBT-1, OCE-205, and other emerging candidates are anticipated to contribute significantly to the expansion of the Acute Kidney Injury Market in the coming years.
DelveInsight has released a new report titled “Acute Kidney Injury – Market Insights, Epidemiology, and Market Forecast-2034,” offering a comprehensive analysis of Acute Kidney Injury, including historical and projected epidemiology along with detailed market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Acute Kidney Injury market report
Some of the key facts of the Acute Kidney Injury Market Report:
- The incidence of AKI is steadily increasing, particularly among patients suffering from acute medical illnesses or those undergoing complex surgical procedures.
- In 2022, approximately 14.6 million mortality-adjusted incident cases of AKI were reported among hospitalized patients across the 7MM. The United States accounted for the highest proportion of cases among the major markets, representing nearly 39% of the total.
- In the same year, the U.S. also dominated the AKI market, capturing around 65% of the overall market share across the 7MM. This dominance is expected to increase further through 2034.
- In June 2024, SeaStar Medical achieved an important interim enrollment milestone in its pivotal NEUTRALIZE-AKI adult trial evaluating the Selective Cytopheretic Device (SCD). A Data Safety Monitoring Board (DSMB) review is anticipated in mid-2025.
- Earlier, in December 2023, SeaStar Medical initiated patient enrollment in the NEUTRALIZE-AKI clinical study, which assesses the effectiveness of its cell-targeted Selective Cytopheretic Device (SCD) in critically ill adults with AKI requiring continuous kidney replacement therapy (CKRT).
- In October 2023, Renibus Therapeutics treated the first patient in its pivotal Phase III PROTECT trial investigating RBT-1, aimed at reducing complications following cardiac surgery. Top-line results are expected by mid-2025, with a potential NDA submission planned for early 2026.
- Key companies involved in the development of innovative AKI therapies include Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics, Alloksys, and Vifor Pharma, among others.
- Promising therapies currently under investigation for Acute Kidney Injury include RBT-1, OCE-205, and several other candidates.
Acute Kidney Injury Overview
Acute Kidney Injury (AKI) is characterized by a rapid decline in kidney function. Clinically, it is identified by a temporary increase in nitrogen-containing waste products such as blood urea nitrogen (BUN) and serum creatinine, typically developing over a period ranging from several hours to a few weeks.
Common symptoms associated with AKI may include nausea, vomiting, fatigue, dizziness, and lower back pain. However, some patients may remain asymptomatic, while others may present with vague or non-specific symptoms that are not immediately linked to kidney dysfunction.
Acute Kidney Injury Market Insights
Patients diagnosed with Acute Kidney Injury are often managed using diuretics, with loop diuretics being the most frequently prescribed. Among these, furosemide is widely utilized across different stages of AKI due to its ability to promote the excretion of large volumes of water and electrolytes, particularly when the kidneys still maintain some filtering capacity.
Acute Kidney Injury Market Outlook
The Acute Kidney Injury therapeutics market is expected to grow due to the increasing incidence of the condition and the advancement of innovative therapies with novel mechanisms of action. The current treatment paradigm is largely dominated by renal replacement therapy (RRT) and the off-label use of drugs such as ACE inhibitors, ARBs, diuretics, and NSAIDs, highlighting the absence of targeted pharmacological treatments.
Several comorbidities—including cardiovascular diseases, hypertension, diabetes, chronic kidney disease (CKD), and impaired renal recovery—significantly increase the risk of AKI development. While conventional treatment strategies continue to dominate, the future AKI market landscape is expected to evolve as new therapies target specific causes such as sepsis-related AKI, cardiac surgery complications, and delayed graft function.
Emerging pipeline therapies are specifically addressing distinct forms of AKI, including hepatorenal syndrome-associated AKI (HRS-AKI), sepsis-induced AKI, and post-cardiac procedure AKI. These developments are expected to address substantial unmet medical needs in the treatment landscape.
Discover how the Acute Kidney Injury market is rising in the coming years @ https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=mpr
Key Acute Kidney Injury Market Companies
Key companies involved in the development of innovative AKI therapies include
- Atox Bio,
- AM-Pharma Holding,
- Quark-Pharmaceuticals,
- LG Chem,
- Pharming Group,
- Angion Biomedica,
- Elysium Health,
- Sentien Biotechnologies,
- Pharmazz, Arch Biopartners,
- Guard Therapeutics,
- RegeneRx Biopharmaceuticals,
- Cerenis Therapeutics,
- Alloksys,
- Vifor Pharma, among others.
Acute Kidney Injury Emerging Drugs
Leading companies working on innovative AKI treatments include Renibus Therapeutics (RBT-1), Ocelot Bio (OCE-205), AM-Pharma (Ilofotase alfa), and Guard Therapeutics (RMC-035). These organizations are focusing on therapies designed to improve clinical outcomes and reduce mortality rates in hospitalized patients. Overall, the AKI therapeutics market is projected to witness consistent growth during the forecast period 2024–2034.
Scope of the Acute Kidney Injury Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Kidney Injury Companies: Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics, Alloksys, Vifor Pharma, and others
Acute Kidney Injury Therapies: RBT-1, OCE-205, and others
Acute Kidney Injury Therapeutic Assessment: Current marketed therapies and emerging treatment options for Acute Kidney Injury
Acute Kidney Injury Market Dynamics: Market drivers and barriers influencing the Acute Kidney Injury landscape
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s Five Forces, BCG Matrix, and market entry strategies
Acute Kidney Injury Unmet Needs, KOL’s views, Analyst’s views, Acute Kidney Injury Market Access and Reimbursement
To know what’s more in our Acute Kidney Injury report, visit https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=mpr
Key benefits of the Acute Kidney Injury Market Report:
The report provides a detailed overview and comprehensive insights into the Acute Kidney Injury epidemiology and market landscape across the 7MM (United States, EU5 — Germany, Spain, France, Italy, United Kingdom — and Japan).
The report offers detailed insights into both current treatment approaches and emerging therapies for Acute Kidney Injury.
It presents a historical as well as forecasted global market outlook, covering therapy adoption trends across the 7MM.
The report delivers strategic insights that help organizations develop effective business strategies by understanding the key trends driving the Acute Kidney Injury market.Got queries? Click here to know more about the Acute Kidney Injury market Landscape: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=mpr
